Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis

BACKGROUND: It remains uncertain whether neoadjuvant immune checkpoint inhibitor (nICI) is superior to neoadjuvant chemotherapy (nCT) in resectable non-small cell lung cancer. In addition, there are outstanding questions for nICI such as the ideal treatment mode and predictors. METHODS: PubMed, Emba...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, He, Liu, Tingting, Chen, Jun, Dang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533019/
https://www.ncbi.nlm.nih.gov/pubmed/36212419
http://dx.doi.org/10.3389/fonc.2022.901494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9533019/
https://www.ncbi.nlm.nih.gov/pubmed/36212419
http://dx.doi.org/10.3389/fonc.2022.901494

Ejemplares similares